These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22632606)

  • 1. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.
    Williams PD; Zlokovic BV; Griffin JH; Pryor KE; Davis TP
    Curr Pharm Des; 2012; 18(27):4215-22. PubMed ID: 22632606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.
    Wang Y; Thiyagarajan M; Chow N; Singh I; Guo H; Davis TP; Zlokovic BV
    Stroke; 2009 May; 40(5):1864-9. PubMed ID: 19057019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.
    Wang Y; Zhao Z; Chow N; Ali T; Griffin JH; Zlokovic BV
    Brain Res; 2013 Apr; 1507():97-104. PubMed ID: 23438513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
    Lyden P; Pryor KE; Coffey CS; Cudkowicz M; Conwit R; Jadhav A; Sawyer RN; Claassen J; Adeoye O; Song S; Hannon P; Rost NS; Hinduja A; Torbey M; Lee JM; Benesch C; Rippee M; Rymer M; Froehler MT; Clarke Haley E; Johnson M; Yankey J; Magee K; Qidwai J; Levy H; Mark Haacke E; Fawaz M; Davis TP; Toga AW; Griffin JH; Zlokovic BV;
    Ann Neurol; 2019 Jan; 85(1):125-136. PubMed ID: 30450637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity.
    Guo H; Wang Y; Singh I; Liu D; Fernández JA; Griffin JH; Chow N; Zlokovic BV
    J Neurochem; 2009 Apr; 109(1):116-24. PubMed ID: 19166505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice.
    Wang Y; Zhao Z; Rege SV; Wang M; Si G; Zhou Y; Wang S; Griffin JH; Goldman SA; Zlokovic BV
    Nat Med; 2016 Sep; 22(9):1050-5. PubMed ID: 27548576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model.
    Fernández JA; Xu X; Liu D; Zlokovic BV; Griffin JH
    Blood Cells Mol Dis; 2003; 30(3):271-6. PubMed ID: 12737945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoprotective-selective activated protein C therapy for ischaemic stroke.
    Mosnier LO; Zlokovic BV; Griffin JH
    Thromb Haemost; 2014 Nov; 112(5):883-92. PubMed ID: 25230930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity.
    Guo H; Singh I; Wang Y; Deane R; Barrett T; Fernández JA; Chow N; Griffin JH; Zlokovic BV
    Eur J Neurosci; 2009 Mar; 29(6):1119-30. PubMed ID: 19302148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.
    Wang Y; Zhao Z; Chow N; Rajput PS; Griffin JH; Lyden PD; Zlokovic BV
    Stroke; 2013 Dec; 44(12):3529-36. PubMed ID: 24159062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers.
    Lyden P; Levy H; Weymer S; Pryor K; Kramer W; Griffin JH; Davis TP; Zlokovic B
    Curr Pharm Des; 2013; 19(42):7479-85. PubMed ID: 24372304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.
    Wang Y; Sinha RK; Mosnier LO; Griffin JH; Zlokovic BV
    Blood Cells Mol Dis; 2013 Aug; 51(2):104-8. PubMed ID: 23541526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
    Wang Y; Zhang Z; Chow N; Davis TP; Griffin JH; Chopp M; Zlokovic BV
    Stroke; 2012 Sep; 43(9):2444-9. PubMed ID: 22811462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 3K3A-Activated Protein C to Treat Neonatal Hypoxic Ischemic Brain Injury in the Spiny Mouse.
    Ellery SJ; Goss MG; Brew N; Dickinson H; Hale N; LaRosa DA; Walker DW; Wong FY
    Neurotherapeutics; 2019 Jan; 16(1):231-243. PubMed ID: 30225791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact.
    Walker CT; Marky AH; Petraglia AL; Ali T; Chow N; Zlokovic BV
    Brain Res; 2010 Aug; 1347():125-31. PubMed ID: 20513369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
    Mukherjee P; Lyden P; Fernández JA; Davis TP; Pryor KE; Zlokovic BV; Griffin JH
    Stroke; 2020 Jul; 51(7):2236-2239. PubMed ID: 32568648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant signalling-selective activated protein C that lacks anticoagulant activity is efficacious and safe in cutaneous wound preclinical models.
    Zhao R; Xue M; Lin H; Smith M; Liang H; Weiler H; Griffin JH; Jackson CJ
    Wound Repair Regen; 2024; 32(1):90-103. PubMed ID: 38155595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.
    Griffin JH; Mosnier LO; Fernández JA; Zlokovic BV
    Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2143-2151. PubMed ID: 27758767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection and vasculoprotection using genetically targeted protease-ligands.
    Rajput PS; Lamb JA; Fernández JÁ; Bai J; Pereira BR; Lei IF; Leung J; Griffin JH; Lyden PD
    Brain Res; 2019 Jul; 1715():13-20. PubMed ID: 30880117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3K3A-Activated Protein C Inhibits Choroidal Neovascularization Growth and Leakage and Reduces NLRP3 Inflammasome, IL-1β, and Inflammatory Cell Accumulation in the Retina.
    Weinberger Y; Budnik I; Nisgav Y; Palevski D; Ben-David G; Fernández JA; Margalit SN; Levy-Mendelovich S; Kenet G; Weinberger D; Griffin JH; Livnat T
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.